Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants

SARS-CoV-2 在免疫抑制的 COVID-19 患者体内的宿主内进化是免疫逃逸变异株的来源

阅读:4
作者:Sebastian Weigang # ,Jonas Fuchs # ,Gert Zimmer ,Daniel Schnepf ,Lisa Kern ,Julius Beer ,Hendrik Luxenburger ,Jakob Ankerhold ,Valeria Falcone ,Janine Kemming ,Maike Hofmann ,Robert Thimme ,Christoph Neumann-Haefelin ,Svenja Ulferts ,Robert Grosse ,Daniel Hornuss ,Yakup Tanriver ,Siegbert Rieg ,Dirk Wagner ,Daniela Huzly ,Martin Schwemmle ,Marcus Panning ,Georg Kochs

Abstract

The origin of SARS-CoV-2 variants of concern remains unclear. Here, we test whether intra-host virus evolution during persistent infections could be a contributing factor by characterizing the long-term SARS-CoV-2 infection dynamics in an immunosuppressed kidney transplant recipient. Applying RT-qPCR and next-generation sequencing (NGS) of sequential respiratory specimens, we identify several mutations in the viral genome late in infection. We demonstrate that a late viral isolate exhibiting genome mutations similar to those found in variants of concern first identified in UK, South Africa, and Brazil, can escape neutralization by COVID-19 antisera. Moreover, infection of susceptible mice with this patient's escape variant elicits protective immunity against re-infection with either the parental virus and the escape variant, as well as high neutralization titers against the alpha and beta SARS-CoV-2 variants, B.1.1.7 and B.1.351, demonstrating a considerable immune control against such variants of concern. Upon lowering immunosuppressive treatment, the patient generated spike-specific neutralizing antibodies and resolved the infection. Our results suggest that immunocompromised patients could be a source for the emergence of potentially harmful SARS-CoV-2 variants.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。